Compare PFIS & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFIS | SLDB |
|---|---|---|
| Founded | 1905 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.8M | 498.6M |
| IPO Year | 1998 | 2017 |
| Metric | PFIS | SLDB |
|---|---|---|
| Price | $52.00 | $7.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $56.00 | $14.70 |
| AVG Volume (30 Days) | 29.5K | ★ 1.4M |
| Earning Date | 05-01-2026 | 06-22-2026 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | N/A | ★ 36.65 |
| EPS | ★ 4.69 | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $5.85 | N/A |
| P/E Ratio | $11.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.00 | $2.45 |
| 52 Week High | $57.71 | $8.47 |
| Indicator | PFIS | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 61.22 |
| Support Level | $50.56 | $5.16 |
| Resistance Level | $53.27 | N/A |
| Average True Range (ATR) | 1.95 | 0.55 |
| MACD | -0.50 | 0.19 |
| Stochastic Oscillator | 26.52 | 70.47 |
Peoples Financial Services Corp is a bank holding company operating through its subsidiaries. The bank provides a full range of financial services. Its products and services include checking accounts, business accounts, savings accounts, loan products, money market accounts, mortgages, chip-enabled debit cards, credit card processing, and visa master card and advisory services. Its loan portfolio includes Commercial loans, which consist of commercial, commercial real estate, municipal, and other related tax-free loans; and retail loans, which include residential real estate and other consumer loans. The company mainly operates in the United States in Pennsylvania.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.